Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$31.43M$31.43M+18.4% vs Q3 2022 Net Income-$25.01M-$25.01MN/M vs Q3 2022 EPS Diluted-$0.17-$0.17N/M vs Q3 2022 Gross Profit$13,226,000+11.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$9,179,000N/M Free Cash Flowderived-$9,972,000N/M Margins · derivedGross margin42.1%−2.5 pt vs Q3 2022
Operating margin-79.3%+78.4 pt vs Q3 2022
Net margin-79.6%+78.2 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end